Werewolf Therapeutics, Inc. Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc.

HOWL

Rank in Stocks #22440
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Share Price
$1.03
Last synced: 2026-11-18
Market Cap
$50.06M
Change (1 day)
-1.90%
Change (1 year)
17.96%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Werewolf Therapeutics, Inc. (HOWL)

Category

Healthcare
EPS for Werewolf Therapeutics, Inc. (HOWL)
EPS as of September 2026 TTM: $-0.57
According to Werewolf Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.57. At the end of 2025 the company had an EPS of $-1.32, an increase over its 2024 EPS of $-1.63.
EPS history for Werewolf Therapeutics, Inc. from 2019 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.57 -56.82%
2025 $-1.32 -19.02%
2024 $-1.63 55.24%
2023 $-1.05 -43.55%
2022 $-1.86 -83.00%
2021 $-10.94 1,016.33%
2020 $-0.98 157.89%
2019 $-0.38 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$15.66 -2,847.37%
US
$-7.08 1,142.11%
US
$-5.29 828.07%
AU
$21.56 -3,882.46%
NL
$12.73 -2,333.72%
BE

Questions about Werewolf Therapeutics, Inc.'s earnings per share (EPS)

What is Werewolf Therapeutics, Inc.'s earnings per share (EPS)?

Werewolf Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.57, as of Sep 2026.

What was Werewolf Therapeutics, Inc.'s earnings per share (EPS) in 2025?

In 2025, Werewolf Therapeutics, Inc.'s earnings per share (EPS) was $-1.32, compared with $-1.63 in 2024.

How has Werewolf Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Werewolf Therapeutics, Inc.'s earnings per share (EPS) was highest in 2020 ($-0.98) and lowest in 2021 ($-10.94).

How does Werewolf Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?

Werewolf Therapeutics, Inc.'s earnings per share (EPS) ($-0.57) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.